Evaxion Biotech A/S Stock Scheduled to Reverse Split on Monday, January 13th (NASDAQ:EVAX)

Evaxion Biotech A/S (NASDAQ:EVAX) shares are scheduled to reverse split before the market opens on Monday, January 13th. The 1-5 reverse split was announced on Monday, December 30th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, January 10th.

Evaxion Biotech A/S Trading Down 1.5 %

Shares of EVAX stock opened at $0.91 on Friday. The stock has a market cap of $5.34 million, a P/E ratio of -3.14 and a beta of -0.39. Evaxion Biotech A/S has a 1 year low of $0.83 and a 1 year high of $13.61. The company has a current ratio of 1.00, a quick ratio of 2.80 and a debt-to-equity ratio of 7.99. The stock has a 50 day simple moving average of $1.59 and a 200 day simple moving average of $2.47.

Evaxion Biotech A/S (NASDAQ:EVAX) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.08. The company had revenue of $3.02 million during the quarter, compared to analyst estimates of $0.19 million. On average, research analysts predict that Evaxion Biotech A/S will post -0.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective on shares of Evaxion Biotech A/S in a research report on Friday, November 1st.

Institutional Trading of Evaxion Biotech A/S

An institutional investor recently raised its position in Evaxion Biotech A/S stock. Armistice Capital LLC grew its stake in Evaxion Biotech A/S (NASDAQ:EVAX) by 6.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 392,000 shares of the company’s stock after purchasing an additional 25,000 shares during the period. Armistice Capital LLC owned about 7.24% of Evaxion Biotech A/S worth $1,137,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 11.04% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.